

The New York State Department of Health AIDS Institute together with the Institute for Family Health is offering certification training for all Primary Care Providers in NYS on Buprenorphine Treatment for Opioid Dependence.

****Preference will be given to physicians outside of New York City.**

BUPRENORPHINE AND OFFICE-BASED TREATMENT OF **OPIOID DEPENDENCE**

****Free No Registration Fee****

Presented in collaboration with the
American Psychiatric Association

Partially supported by an unrestricted
educational grant from Reckitt Benckiser
Pharmaceuticals

Program Overview

Saturday,

February 27, 2010

8am to 5pm

****CME CREDITS****

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Medical Society of the State of New York (MSSNY) through the joint sponsorship of School of Public Health, University at Albany and NYSDOH CEI (Clinical Education Initiative). The School of Public Health, University at Albany is accredited by the Medical Society of the State of New York (MSSNY) to provide continuing medical education for physicians.

School of Public Health, University at Albany, designates this educational activity for a maximum of 8.0 AMA PRA Category 1 Credits.

- Federal Center for Substance Abuse Treatment (CSAT) endorses this national training initiative.
- At the conclusion of the course, the physician participant will be eligible to request the Secretary of Health and Human services for a waiver of the special registration requirements defined in DATA 2000. When granted, the waiver permits the physician to prescribe buprenorphine in an office or clinic-based setting.
- One-on-one mentoring via phone, email, or site visit is available through the assistance provided via the New York State Department of Health: www.nyhealth.gov/diseases/aids/harm-reduction/buprenorphine.
- One-on-one mentoring via phone, email, or site visit is available through the assistance provided via the Physician Clinical Support System (PCSS), www.pcssmentor.org
- Qualified physicians may dispense or prescribe specifically approved Schedule III, IV and V narcotic medications for treatment of opioid addiction in an office-based setting as part of The Drug Addiction Treatment Act (DATA) 2000.
 - Physicians qualify after completion of not less than eight (8) hours of approved training.
 - This course satisfies the DATA 2000 eight-hour training requirement.

Casperkill Recreation Center

2330 South Road (Rt. 9)

Poughkeepsie, NY 12601

Directions:

http://www.casperkillrec.com/contact_directions.htm

WHO SHOULD ATTEND

This program is recommended for physicians with experience and/or interest in treating opioid dependence. It is also recommended for psychiatric, primary care, HIV, pain, and addiction medicine physicians.

Mandatory Registration begins at 7:00am

TOPICS & EDUCATIONAL OBJECTIVES

<i>Topics</i>	<i>Educational Objectives</i>
<p>Overview of opioid dependence</p> <p>Clinical use of buprenorphine & buprenorphine/naloxone, including induction, maintenance and detoxification, patient assessment and selection, and the efficacy and safety of buprenorphine/naloxone</p> <p>Legislative changes allowing office-based treatment of opioid dependence, including the Drug Addiction Treatment Act of 2000</p> <p>General opioid pharmacology and pharmacology of buprenorphine and buprenorphine/naloxone and efficacy and safety of buprenorphine/naloxone</p> <p>Medical and psychiatric conditions in opioid dependent patients</p> <p>Special treatment populations</p> <p>Office procedures including confidentiality and record keeping</p>	<p>Understand the rationale and need for opioid pharmacotherapy in the treatment of opioid dependence</p> <p>Describe buprenorphine protocols for all phases of treatment and for optimal patient/treatment matching.</p> <p>Understand specific information on the legislative and regulatory history of office-based</p> <p>Understand the pharmacological characteristics of opioids.</p> <p>Identify common co-morbid conditions associated with opioid dependence.</p> <p>Understand treatment issues and management of opioid dependence in adolescents, pregnant women, and patients with acute and/or chronic pain.</p> <p>Describe the resources needed to set up office-based treatment with buprenorphine for patients with opioid dependence.</p>

7:00 AM—8:00 AM Registration, Mandatory Sign-in, and Continental Breakfast

8:00 AM—4:30 PM Program, Including Lunch

4:30 PM Mandatory Sign-Out

PLEASE BRING THE FOLLOWING TO THE MEETING:

- DEA Number
- State Medical License Number
- Photo ID

***Please note that the American Psychiatric Association cannot confirm training for those who arrive late or depart before the completion of the course.**

Program Faculty

Petros Levounis MD, MA
 Director, The Addiction Institute of New York
 Chief, Division of Addiction Psychiatry, The St. Luke's
 & Roosevelt Hospitals; Associate Clinical Professor of Psychiatry,
 Columbia University College of Physicians & Surgeons

Edwin A. Salsitz, MD, FASAM
 Medical Director, Office-Based Opioid Therapy
 Department of Medicine, Beth Israel Medical Center
 New York, NY

Susan Whitley, MD
 Assistant Professor of Psychiatry & Behavioral Sciences and
 Family & Social Medicine,
 Albert Einstein College of Medicine
 Instructor of Psychiatry & Behavioral Sciences and Family
 Medicine and Community Health,
 Albert Einstein College of Medicine

Event Registration Form

“Buprenorphine and Office-Based Treatment of Opioid Dependence”

**Casperkill Recreation Center
2330 South Road (Rt. 9)
Poughkeepsie, NY 12601**

**Saturday,
February 27, 2010
8am to 5pm**

****Free No Registration Fee****

Pre-registration is required, as space is limited and registrations are accepted on a first come, first served basis. **REGISTRATION CLOSES February 20th.**

Full Name:		
Circle One: MD DO NP Resident PA		
Address:		
City:	State:	Zip:
Phone:	Fax:	
Email:		

Complete This Form and Submit by Mail or Fax to:
Maryann Grestini
AIDS Institute
Corning Tower- Rm 421
Empire State Plaza
Albany, NY 12237
Fax: 518-473-8905

“Buprenorphine is the most advance in opioid treatment in the last 30 years.”
- Dr. Alan I. Leshner, former Director of the National Institute on Drug Abuse and Chief Executive Officer of the American Association for the Advancement of Science (AAAS).